Download PDF
Semin Thromb Hemost 2010; 36(6): 571-572
DOI: 10.1055/s-0030-1262877
FOREWORD

© Thieme Medical Publishers

Hemolytic Uremic Syndrome

Reinhard Würzner1 , Lothar-Bernd Zimmerhackl2
  • 1Division of Hygiene and Medical Microbiology, Innsbruck Medical University, Innsbruck, Austria
  • 2Department of Pediatrics, Medical University of Innsbruck, Innsbruck, Austria
Further Information

Publication History

Publication Date:
23 September 2010 (online)

    Permissions and Reprints

Hemolytic uremic syndrome (HUS) is a rare ultra-orphan disease. Since its first description in 1955 by Gasser and coworkers from Switzerland, considerable progress has been achieved, especially in the last 5 years. This work accelerated in the last 24 months because of the introduction of anti-C5, a complement inhibitor with the brand name Soliris (eculizumab).

In this issue of Seminars in Thrombosis and Hemostasis, specialists from around the world describe the latest research achievements concerning HUS. The issue focuses in particular on treatment strategies and future developments.

We hope you will enjoy reading the articles in this issue and that the information will also be useful for your research or in your clinical practice.